NCT06490211

Brief Summary

Obtain puncture or surgically removed tumor tissue samples from patients with urinary tract tumors and perform RNA-sequencing, Single-cell RNA-sequence, Spatial Transcriptomics, Proteomics, and Intratumoral Microbiome.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
6mo left

Started Nov 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress84%
Nov 2023Nov 2026

Study Start

First participant enrolled

November 20, 2023

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

June 30, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 8, 2024

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 20, 2026

Last Updated

July 8, 2024

Status Verified

June 1, 2024

Enrollment Period

3 years

First QC Date

June 30, 2024

Last Update Submit

June 30, 2024

Conditions

Urinary System Carcinoma

Outcome Measures

Primary Outcomes (1)

  • progression-free survival

    2 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with urinary system tumors, including kidney cancer, bladder cancer, prostate cancer, etc.

You may qualify if:

  • Patients were treated for bladder cancer, kidney cancer, and prostate cancer in Wuhan Union Hospital from January 2024 to January 2026;
  • Aged \> 18 years old;
  • Urinalysis, urine exfoliated cells, ultrasound, CT, and MR examinations indicated the above tumors;
  • Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

You may not qualify if:

  • Poor image quality;
  • Incomplete clinical data or loss of follow-up;
  • Presence of another primary malignant tumor other than urinary tract tumor;
  • Unclear pathological diagnosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Union Hospital，Tongji Medical College，Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

RECRUITING

Central Study Contacts

Lian Yang

CONTACT

18986273791yanglian@hust.edu.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 30, 2024

First Posted

July 8, 2024

Study Start

November 20, 2023

Primary Completion (Estimated)

November 20, 2026

Study Completion (Estimated)

November 20, 2026

Last Updated

July 8, 2024

Record last verified: 2024-06

Locations

CN(1)